DOCSLIB.ORG

Over-The-Counter Drug List

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Over-The-Counter Drug List Over-the-Counter Drug List Kentucky Single Medicaid MCO PBM Program Effective July 1, 2021 This list applies only to Kentucky Medicaid Managed Care Organizations (MCO). For Fee-for-Service refer to the OTC list on the Magellan Medicaid Administration website: https://kentucky.magellanmedicaid.com/kentucky/source/index.asp. Inclusion in this list does not guarantee coverage. Quantity, cost, and other limits may apply. Allergy, Cough, and Cold Drugs Tablets and Capsules Drug Name Strength Dosage Form All Day Allergy (cetirizine) tablet Cetirizine HCl 5 mg tablet Cetirizine HCl 10 mg tablet Chlorpheniramine maleate 4 mg tablet Chlorpheniramine maleate ER 12 mg tablet Clemastine fumarate 1.34 mg (1 mg base equiv) tablet Dextromethorphan-guaifenesin 20-400 mg tablet Dextromethorphan-guaifenesin ER 12 hr 30-600 mg tablet Dextromethorphan-guaifenesin ER 12 hr 60-1200 mg tablet Diphenhydramine HCl 25 mg capsule Diphenhydramine HCl 50 mg capsule Diphenhydramine HCl 50 mg tablet Fexofenadine HCl 60 mg tablet Fexofenadine HCl 180 mg tablet Fexofenadine-pseudoephedrine ER 12 hr 60-120 mg tablet Guaifenesin 200 mg tablet Guaifenesin 400 mg tablet Guaifenesin ER 12 hr 600 mg tablet Guaifenesin ER 12 hr 1200 mg tablet Levocetirizine dihydrochloride 5 mg tablet Loratadine 10 mg tablet Loratadine & pseudoephedrine ER 12 hr 5-120 mg tablet Loratadine & pseudoephedrine ER 24 hr 10-240 mg tablet Phenylephrine HCl 10 mg tablet Pseudoephedrine HCl 30 mg tablet Pseudoephedrine HCl ER 12 hr 120 mg tablet Pseudoephedrine-guaifenesin ER 12 hr 60-600 mg tablet Kentucky Medicaid Single MCO PBM OTC List Effective July 1, 2021 1 Copyright © 2021 MedImpact Healthcare Systems, Inc. All rights reserved. Liquids Drug Name Strength Dosage Form Cetirizine HCl 1 mg/ml (5 mg/5ml) syrup Chlorpheniramine maleate 2 mg/5ml syrup Dextromethorphan polistirex ER 30 mg/5ml suspension Dextromethorphan-guaifenesin 5-100 mg/5ml liquid Dextromethorphan-guaifenesin 10-100 mg/5ml liquid Dextromethorphan-guaifenesin 10-100 mg/5ml syrup Dextromethorphan-guaifenesin 10-200 mg/5ml liquid Diphenhydramine HCl 12.5 mg/5ml elixir Diphenhydramine HCl 12.5 mg/5ml liquid Guaifenesin 100 mg/5ml liquid Guaifenesin 100 mg/5ml syrup Guaifenesin-codeine 100-10 mg/5ml solution Loratadine 5 mg/5ml syrup Phenylephrine-brompheniramine-DM 2.5-1-5 mg/5ml elixir Phenylephrine-brompheniramine-DM 2.5-1-5 mg/5ml liquid Pseudoephed-bromphen-DM 15-1-5 mg/5ml elixir Pseudoephed-bromphen-DM 30-2-10 mg/5ml syrup Pseudoephedrine HCl 15 mg/5ml liquid Chewable Tablets Drug Name Strength Dosage Form Diphenhydramine HCl 12.5 mg chewable tablet Loratadine 5 mg chewable tablet Drugs for Acne, Skin, and Warts Creams and Lotions for the Skin Drug Name Strength Dosage Form Benzoyl peroxide 5% lotion Benzoyl peroxide 10% cream Benzoyl peroxide 10% lotion Hydrocortisone 0.5% cream Hydrocortisone 1% lotion Lactic acid (ammonium lactate) 12% cream Lactic acid (ammonium lactate) 12% lotion Selenium sulfide 1% lotion Urea 10% cream Urea 20% cream Urea 30% cream Urea 40% cream Kentucky Medicaid Single MCO PBM OTC List Effective July 1, 2021 2 Copyright © 2021 MedImpact Healthcare Systems, Inc. All rights reserved. Ointments for the Skin Drug Name Strength Dosage Form Hydrocortisone 0.5% ointment Zinc oxide 20% ointment Liquids for the Skin Drug Name Strength Dosage Form Benzoyl peroxide 2.5% liquid Benzoyl peroxide 4% liquid Benzoyl peroxide 5% liquid Benzoyl peroxide 6% liquid Benzoyl peroxide 10% liquid Salicylic acid 17% liquid Gels for the Skin Drug Name Strength Dosage Form Benzoyl peroxide 2.5% gel Benzoyl peroxide 5% gel Benzoyl peroxide 10% gel Birth Control Condoms Drug Name Strength Dosage Form Condoms latex lubricated Condoms latex non-lubricated Emergency Contraceptives Drug Name Strength Dosage Form Levonorgestrel 1.5 mg tablet Women’s Health Vaginal Creams Drug Name Strength Dosage Form Clotrimazole vaginal 1% cream Clotrimazole vaginal 2% cream Miconazole vaginal 2% cream Miconazole vaginal 4% cream Kentucky Medicaid Single MCO PBM OTC List Effective July 1, 2021 3 Copyright © 2021 MedImpact Healthcare Systems, Inc. All rights reserved. Kits Drug Name Strength Dosage Form Miconazole vaginal 2% applicator and cream kit Miconazole vaginal 2% suppository and cream kit Vaginal Suppositories Drug Name Strength Dosage Form Miconazole vaginal 100 mg suppository Tablets Drug Name Strength Dosage Form Phenazopyridine HCl 95 mg tablet Diabetes Drugs Insulins Drug Name Strength Dosage Form Humulin N NPH U-100 vial Humulin N NPH U-100 KwikPen Glucose Drug Name Strength Dosage Form Glucose 4 gm chewable tablet Metabolic Aids Drug Name Strength Dosage Form Levocarnitine 1 gm/10ml (10%) solution Levocarnitine 330 mg tablet Ear, Eye, Mouth, and Nose Drugs Ear Drops Drug Name Strength Dosage Form Carbamide peroxide 6.5% otic solution Kentucky Medicaid Single MCO PBM OTC List Effective July 1, 2021 4 Copyright © 2021 MedImpact Healthcare Systems, Inc. All rights reserved. Eye Drops Drug Name Strength Dosage Form Artificial tears ophthalmic solution Carboxymethylcellulose sodium 0.5% ophthalmic solution Dextran 70-hypromellose 0.1-0.3% ophthalmic solution Ketotifen fumarate 0.025% (base equiv) ophthalmic solution Polyethylene gly-propylene gly 0.4-0.3% ophthalmic solution Polyvinyl alcohol 1.4% ophthalmic solution Mouth Drug Name Strength Dosage Form Benzocaine-menthol 15-3.6 mg lozenge Chlorhexidine gluconate 4% liquid Sodium fluoride 1.1% cream Sodium fluoride 1.1% (0.5% f) gel Nose Sprays Drug Name Strength Dosage Form Budesonide 32 mcg/act nasal spray Cromolyn sodium 5.2 mg/act (4%) nasal spray Oxymetazoline 0.05% nasal spray Saline 0.65% nasal spray Triamcinolone acetonide 55 mcg/act nasal spray Digestive and Laxative Drugs Tablets and Capsules Drug Name Strength Dosage Form Bisacodyl delayed release 5 mg tablet Bismuth subsalicylate 262 mg tablet Calcium polycarbophil 625 mg tablet Docusate calcium 240 mg capsule Docusate sodium 100 mg capsule Docusate sodium 100 mg tablet Docusate sodium 250 mg capsule Lactobacillus-inulin capsule Loperamide HCl 2 mg tablet Magnesium oxide 400 mg tablet Magnesium oxide 420 mg tablet Omeprazole delayed release 20 mg tablet Omeprazole magnesium delayed release 20 mg tablet Psyllium 0.52 gm capsule Sennosides 8.6 mg tablet Continued on next page Kentucky Medicaid Single MCO PBM OTC List Effective July 1, 2021 5 Copyright © 2021 MedImpact Healthcare Systems, Inc. All rights reserved. Digestive and Laxative Drugs, Continued Sennosides 25 mg tablet Sennosides-docusate sodium 8.6-50 mg tablet Simethicone 125 mg capsule Simethicone 180 mg capsule Sodium bicarbonate 325 mg tablet Sodium bicarbonate 650 mg tablet Chewable Tablets Drug Name Strength Dosage Form Alum hydroxide-magnesium carb 160-105 mg chewable tablet Alum hydroxide-magnesium trisilicate 80-20 mg chewable tablet Alum-mag hydroxide-simethicone 200-200-25 mg chewable tablet Bismuth subsalicylate 262 mg chewable tablet Calcium carbonate (antacid) 648 mg chewable tablet Calcium carbonate (antacid) 500 mg chewable tablet Calcium carbonate (antacid) 750 mg chewable tablet Calcium carbonate (antacid) 1000 mg chewable tablet Meclizine HCl 25 mg chewable tablet Simethicone 80 mg chewable tablet Simethicone 125 mg chewable tablet Liquids Drug Name Strength Dosage Form Alum hydroxide-magnesium carb 95-358 mg/15ml suspension Alum-mag hydroxide-simethicone 200-200-20 mg/5ml suspension Alum-mag hydroxide-simethicone 400-400-40 mg/5ml suspension Bismuth subsalicylate 262 mg/15ml suspension Bismuth subsalicylate 525 mg/15ml suspension Calcium carbonate (antacid) 1250 mg/5ml suspension Docusate sodium 50 mg/15ml liquid Docusate sodium 60 mg/15ml syrup Docusate sodium 150 mg/15ml liquid Magnesium citrate solution Magnesium hydroxide 400 mg/5ml suspension Sennosides 8.8 mg/5ml syrup Simethicone 40 mg/0.6ml suspension Powders Drug Name Strength Dosage Form Polyethylene glycol 3350 oral 17 gm packet Polyethylene glycol 3350 oral 17 gm/scoop powder Psyllium 28.3% powder Psyllium 30.9% powder Psyllium 33% powder Psyllium 48.57% powder Psyllium 58.6% powder Psyllium 95% powder Kentucky Medicaid Single MCO PBM OTC List Effective July 1, 2021 6 Copyright © 2021 MedImpact Healthcare Systems, Inc. All rights reserved. Enemas and Suppositories Drug Name Strength Dosage Form Bisacodyl 10 mg suppository Glycerin 1.2 gm suppository Glycerin 2 gm suppository Sodium phosphates enema Vitamins Tablets and Capsules Drug Name Strength Dosage Form Ascorbic acid 250 mg tablet Ascorbic acid 500 mg tablet B-complex w/ C & folic acid 0.8 mg tablet Calcium carbonate 600 mg tablet Calcium carbonate 1250 mg (500 mg elemtl Ca) tablet Calcium carbonate 1500 mg (600 mg elemtl Ca) tablet Calcium carbonate-cholecalciferol 250 mg-125 unit tablet Calcium carbonate-cholecalciferol 500 mg-200 unit tablet Calcium carbonate-cholecalciferol 500 mg-400 unit tablet Calcium carbonate-cholecalciferol 600 mg-200 unit tablet Calcium carbonate-cholecalciferol 600 mg-400 unit tablet Calcium carbonate-cholecalciferol 600 mg-800 unit tablet Calcium carbonate-ergocalciferol 500mg-200 unit tablet Calcium carbonate-vitamin D 250 mg-125 unit tablet Calcium carbonate-vitamin D 500 mg-125 unit tablet Calcium carbonate-vitamin D 500 mg-200 unit tablet Calcium carbonate-vitamin D 500 mg-400 unit tablet Calcium carbonate-vitamin D 600 mg-200 unit tablet Calcium carbonate-vitamin D 600 mg-400 unit tablet Calcium citrate 950 mg (200 mg elemtl Ca) tablet Calcium citrate-vitamin d 315 mg-200 unit (elemtl Ca) tablet Calcium cit-vitamin d 315 mg-250 unit (elemtl Ca) tablet Cholecalciferol 1.25 mg (50000 unit) capsule Cholecalciferol 10 mcg (400 unit) tablet Cholecalciferol 25 mcg (1000 unit) capsule Cholecalciferol 25 mcg (1000 unit) tablet Cholecalciferol 50 mcg (2000 unit) capsule Cholecalciferol 50 mcg (2000 unit) tablet Cholecalciferol 125 mcg (5000 unit) capsule Cholecalciferol 125 mcg (5000 unit) tablet Cyanocobalamin 250 mcg tablet Cyanocobalamin 500 mcg tablet Cyanocobalamin ER 1000 mcg tablet Ferrous fum 324 mg (106 mg elem fe) tablet Ferrous fum 325 mg (106 mg elem fe) tablet Continued on next page Kentucky Medicaid Single MCO PBM OTC List Effective July 1, 2021 7 Copyright © 2021 MedImpact Healthcare Systems, Inc.
Load more

Recommended publications
  • Does Dietary Fiber Affect the Levels of Nutritional Components After Feed Formulation?
    fibers Article Does Dietary Fiber Affect the Levels of Nutritional Components after Feed Formulation? Seidu Adams 1 ID , Cornelius Tlotliso Sello 2, Gui-Xin Qin 1,3,4, Dongsheng Che 1,3,4,* and Rui Han 1,3,4 1 College of Animal Science and Technology, Jilin Agricultural University, Changchun 130118, China; [email protected] (S.A.); [email protected] (G.-X.Q.); [email protected] (R.H.) 2 College of Animal Science and Technology, Department of Animal Genetics, Breeding and Reproduction, Jilin Agricultural University, Changchun 130118, China; [email protected] 3 Key Laboratory of Animal Production, Product Quality and Security, Jilin Agricultural University, Ministry of Education, Changchun 130118, China 4 Jilin Provincial Key Laboratory of Animal Nutrition and Feed Science, Jilin Agricultural University, Changchun 130118, China * Correspondence: [email protected]; Tel.: +86-136-4431-9554 Received: 12 January 2018; Accepted: 25 April 2018; Published: 7 May 2018 Abstract: Studies on dietary fiber and nutrient bioavailability have gained an increasing interest in both human and animal nutrition. Questions are increasingly being asked regarding the faith of nutrient components such as proteins, minerals, vitamins, and lipids after feed formulation. The aim of this review is to evaluate the evidence with the perspective of fiber usage in feed formulation. The consumption of dietary fiber may affect the absorption of nutrients in different ways. The physicochemical factors of dietary fiber, such as fermentation, bulking ability, binding ability, viscosity and gel formation, water-holding capacity and solubility affect nutrient absorption. The dietary fiber intake influences the different methods in which nutrients are absorbed.
    [Show full text]
  • Softgels' Clear Advantages
    DEEPDIVE REPORT March 2019 naturalproductsinsider.com Softgels’ Clear Advantages Report brought to you by DEEPDIVE REPORT Softgels’ Clear Advantages Contents Market snapshot ..................................................................................... 3 Consumer appeal .................................................................................... 4 Softgel history .......................................................................................... 6 Advantages of softgels ........................................................................... 7 How softgels are made .......................................................................... 9 Softgel challenges and solutions .......................................................11 Oxidation ...........................................................................................11 Consumer experience .......................................................................12 Dietary considerations ......................................................................12 Shelf stability ....................................................................................14 Bioavailability ....................................................................................14 Innovative developments .....................................................................16 Copyright © 2019 Informa Exhibitions LLC. All rights reserved. The publisher reserves the right to accept or reject any advertising or editorial material. Advertisers, and/or their agents, assume the
    [Show full text]
  • Oral Drug Delivery: Formulation Selection Methods & Novel Delivery Technologies
    ORAL DRUG DELIVERY: FORMULATION SELECTION METHODS & NOVEL DELIVERY TECHNOLOGIES OUTSTANDING ISSUE SPONSOR www.ondrugdelivery.com “Oral Drug Delivery: Formulation Selection Approaches CONTENTS & Novel Delivery Technologies” This edition is one in the ONdrugDelivery series of pub- No Longer a Hit-or-Miss Proposition: lications from Frederick Furness Publishing. Each issue focuses on a specific topic within the field of drug deliv- Once-Daily Formulation for Drugs with ery, and is supported by industry leaders in that field. pH-Dependent Solubility Gopi Venkatesh, Director of R&D & Anthony Recupero, EDITORIAL CALENDAR 2011: Senior Director, Business Development June: Injectable Drug Delivery (Devices Focus) Aptalis Pharmaceutical Technologies 4-8 July: Injectable Drug Delivery (Formulations Focus) September: Prefilled Syringes A possible approach for the desire to innovate October: Oral Drug Delivery Brian Wang, CEO & Dr Junsang Park, CSO November: Pulmonary & Nasal Drug Delivery (OINDP) GL PharmTech 10-13 December: Delivering Biotherapeutics SUBSCRIPTIONS: COMPANY PROFILE - To arrange your FREE subscription (pdf or print) to Mayne Pharma International 14-15 ONdrugDelivery, contact: Guy Furness, Publisher From Powder to Pill: A Rational Approach to T: +44 (0) 1273 78 24 24 E: [email protected] Formulating for First-into-Man Studies Dr Robert Harris, Director, Early Development SPONSORSHIP/ADVERTISING: Molecular Profiles Ltd 16-19 To feature your company in ONdrugDelivery, contact: Guy Furness, Publisher LiquiTime* Oral Liquid
    [Show full text]
  • Oral Dosage Forms That Should Not Be Crushed Formulary-Specific List for VCMC and SPH
    Oral Dosage Forms That Should Not be Crushed Formulary-Specific List for VCMC and SPH Generic Brand Dosage Form(s) Reasons/Comments amoxicillin-clavulanate Augmentin XR Tablet Slow-release (b,h) aspirin Aspirin EC Caplet; Tablet Slow-release; Enteric-coated aspirin and dipyridamole Aggrenox XR Capsule Slow-release atazanavir Reyataz Capsule Note: an oral powder is available, see prescribing information for administration instructions atomoxetine Strattera Capsule Note: capsule contents can cause ocular irritation - Do not open capsules as contents are an ocular irritant benzonatate Tessalon Perles Capsule Note: swallow whole; local anesthesia of the oral mucosa; choking could occur - Capsules are liquid-filled “perles” - Do not alter (break, cut, chew) integrity of dosage form; local mucosal irritant and anesthetic bisacodyl Dulcolax Capsule; Tablet Enteric-coated (c) bosentan Tracleer Tablet Note: women who are, or may become, pregnant, should not handle crushed or broken tablets brivaracetam Briviact Tablet Film-coated (b) budesonide Entocort EC Capsule Enteric-coated (a) - Capsules contain enteric-coated granules in extended-release matrix; can open capsules but do not crush contents - Products are formulated to release active drug at mid- to late small intestine buPROPion Wellbutrin XL Tablet Slow-release - Do not crush extended-release tablets - Immediate-release tablet products may be film-coated March 2019 carvedilol phosphate Coreg CR Capsule Slow-release (a) (Note: may add contents of capsule to chilled, not warm, applesauce
    [Show full text]
  • A Randomized and Observer Blinded Comparison of Continuous Femoral
    a & hesi C st lin e ic n a l A f R Möller. J Anesthe Clinic Res 2011, 4:1 o e l s e a Journal of Anesthesia & Clinical DOI: 10.4172/2155-6148.1000.277 a n r r c u h o J ISSN: 2155-6148 Research Case Report Open Access A Randomized and Observer Blinded Comparison of Continuous Femoral Block and Fascia Iliaca Compartment Block in Hip Replacement Surgery Thorsten Möller1,2, Sabine Benthaus2, Maria Huber2, Ingrid Bentrup2, Markus Schofer3, Leopold Eberhart2, Hinnerk Wulf2 and Astrid Morin2* 1Department of Anesthesiology and Intensive Care Medicine, Charité-Universitätsmedizin Berlin, Berlin, Germany 2Department of Anesthesiology and Critical Care Medicine, Philipps-University Marburg, Marburg, Germany 3Department of Orthopedy and Rheumatology, Philipps-University Marburg, Marburg, Germany Abstract Background: Techniques, analgesic effects and functional outcome of continuous femoral nerve and fascia iliaca compartment blocks were compared in patients undergoing hip replacement surgery. Methods: 80 patients were enroled in this randomized and observer-blinded study. 40 patients received a femoral nerve catheter with a stimulating catheter (FEM group) and 40 patients a fascia iliaca compartment catheter (FIC group). Before surgery, the catheters were placed. 50 mL prilocaine 1% was administered and a continuous infusion of ropivacaine 0.2% was maintained for 24 hours. Postoperative pain management with non-steroidal anti- inflammatory agents was standardized during the first 24 hours. No bolus application of a local anesthetic was allowed during this period. Intravenous opioide PCA with piritramide (comparable with morphin) was provided for 24 hours, and the patients were instructed to titrate their pain below a level of visual analogue scale of 3.
    [Show full text]
  • Continuous Pericapsular Nerve Group Block for Postoperative Pain
    Fujino et al. JA Clinical Reports (2021) 7:22 https://doi.org/10.1186/s40981-021-00423-1 CASE REPORT Open Access Continuous pericapsular nerve group block for postoperative pain management in total hip arthroplasty: report of two cases Takashi Fujino1* , Masahiko Odo1, Hisako Okada1, Shinji Takahashi2 and Toshihiro Kikuchi1 Abstract Background: Total hip arthroplasty (THA) is one of the surgical procedures associated with severe postoperative pain. Appropriate postoperative pain management is effective for promoting early ambulation and reducing the length of hospital stay. Effects of conventional pain management strategies, such as femoral nerve block and fascia iliaca block, are inadequate in some cases. Case presentation: THA was planned for 2 patients with osteoarthritis. In addition to general anesthesia, continuous pericapsular nerve group (PENG) block and lateral femoral cutaneous nerve (LFCN) block were performed for postoperative pain management. Numerical rating scale (NRS) scores measured at rest and upon movement were low at 2, 12, 24, and 48 h postoperatively, suggesting that the treatments were effective for managing postoperative pain. The Bromage score at postoperative days (POD) 1 and 2 was 0. Conclusion: Continuous PENG block and LFCN block were effective for postoperative pain management in patients who underwent THA. PENG block did not cause postoperative motor blockade. Keywords: Pericapsular nerve group (PENG) block, Continuous peripheral nerve block, Total hip arthroplasty, Peripheral nerve block Background reported that it was more effective for managing postop- Total hip arthroplasty (THA) is associated with signifi- erative pain associated with THA than conventional cant postoperative pain [1]. Opioids are typically used peripheral nerve blocks [6].
    [Show full text]
  • Guidelines on Food Fortification with Micronutrients
    GUIDELINES ON FOOD FORTIFICATION FORTIFICATION FOOD ON GUIDELINES Interest in micronutrient malnutrition has increased greatly over the last few MICRONUTRIENTS WITH years. One of the main reasons is the realization that micronutrient malnutrition contributes substantially to the global burden of disease. Furthermore, although micronutrient malnutrition is more frequent and severe in the developing world and among disadvantaged populations, it also represents a public health problem in some industrialized countries. Measures to correct micronutrient deficiencies aim at ensuring consumption of a balanced diet that is adequate in every nutrient. Unfortunately, this is far from being achieved everywhere since it requires universal access to adequate food and appropriate dietary habits. Food fortification has the dual advantage of being able to deliver nutrients to large segments of the population without requiring radical changes in food consumption patterns. Drawing on several recent high quality publications and programme experience on the subject, information on food fortification has been critically analysed and then translated into scientifically sound guidelines for application in the field. The main purpose of these guidelines is to assist countries in the design and implementation of appropriate food fortification programmes. They are intended to be a resource for governments and agencies that are currently implementing or considering food fortification, and a source of information for scientists, technologists and the food industry. The guidelines are written from a nutrition and public health perspective, to provide practical guidance on how food fortification should be implemented, monitored and evaluated. They are primarily intended for nutrition-related public health programme managers, but should also be useful to all those working to control micronutrient malnutrition, including the food industry.
    [Show full text]
  • Capsule Robot: a Theranostic Approach
    Acta Scientific Pharmaceutical Sciences (ISSN: 2581-5423) Volume 3 Issue 10 October 2019 Review Article Capsule Robot: A Theranostic Approach Pradnya Palekar Shanbhag*, Tejal Gawade, Prerna Patil and Priyanka Deshmukh Department of Pharmaceutics, Oriental College of Pharmacy, Sanpada, Navi Mumbai, Affiliated to University of Mumbai, India *Corresponding Author: Pradnya Palekar Shanbhag, Head and Professor, Department of Pharmaceutics, Oriental College of Pharmacy, Sanpada,Received: Navi September Mumbai, 11, Affiliated 2019 ; Published: to University September of Mumbai, 27, India. 2019 DOI: 10.31080/ASPS.2019.03.0407 Abstract Increasing development in healthcare systems and availability of efficient miniaturized components or systems that are economic has led to profound scope for research in many new fields. Capsule robot was one such fictional idea that turned into factual reality because of use of applicative miniaturized components. Initially capsule robots were developed for endoscopic applications. These travel inside the gastrointestinal tract and thus capture images of the gastrointestinal tract and related areas. Later, capsule robots were developed to be used as the unique tool to construct micron and sub-micron sized drug delivery systems for target delivery and treatment. This article highlights on various aspects of capsule robots in diagnosis and therapy of various disorders and diseases, togetherKeywords: called Capsule theranostic Robot; approachEndoscopy; in Diagnosis;drug delivery Therapy systems. Introduction The rising demand for non invasive methodology for diagnosis controlled manner, Drug Delivery System (DDS) capsule endoscopy was designed. There are quite a number of research studies using rine type capsules which travel inside the body were used for en Microelectromechanical Systems (MEMS) for evaluating the drug and treatment led to the invention of capsule robots.
    [Show full text]
  • Analysis of Phenolic and Cyclic Compounds in Plants Using Derivatization Techniques in Combination with GC-MS-Based Metabolite Profiling
    Molecules 2015, 20, 3431-3462; doi:10.3390/molecules20023431 OPEN ACCESS molecules ISSN 1420-3049 www.mdpi.com/journal/molecules Review Analysis of Phenolic and Cyclic Compounds in Plants Using Derivatization Techniques in Combination with GC-MS-Based Metabolite Profiling Jens Rohloff Department of Biology, Norwegian University of Science and Technology, Trondheim 7491, Norway; E-Mail: [email protected]; Tel.: +47-7359-6093; Fax: +47-7359-6100 Academic Editor: Derek J. McPhee Received: 18 December 2014 / Accepted: 10 February 2015 / Published: 17 February 2015 Abstract: Metabolite profiling has been established as a modern technology platform for the description of complex chemical matrices and compound identification in biological samples. Gas chromatography coupled with mass spectrometry (GC-MS) in particular is a fast and accurate method widely applied in diagnostics, functional genomics and for screening purposes. Following solvent extraction and derivatization, hundreds of metabolites from different chemical groups can be characterized in one analytical run. Besides sugars, acids, and polyols, diverse phenolic and other cyclic metabolites can be efficiently detected by metabolite profiling. The review describes own results from plant research to exemplify the applicability of GC-MS profiling and concurrent detection and identification of phenolics and other cyclic structures. Keywords: derivatization; food chemistry; gas chromatography; mass spectrometry; phenols; phenolic acids 1. Introduction Chromatographic techniques for the detection and identification of metabolites in plant material have undergone major changes in recent years due to improvements of analysis time, detection limit and separation characteristics. Depending on the biological question, one might distinguish between targeted and non-targeted strategies. Gas chromatography (GC) in particular is characterized by sensitivity and reliability of separations and detection of complex sample mixtures.
    [Show full text]
  • Quali-V Extra Dry: a Novel Capsule for Delivering Hygroscopic Pharmaceutical Drugs
    H&TQualicaps Presspart QUALI-V EXTRA DRY: A NOVEL CAPSULE FOR DELIVERING HYGROSCOPIC PHARMACEUTICAL DRUGS In this article, Jose Luis Encinas, Engineering & Continuous Improvement Manager, and Susana Ecenarro, Director of Scientific Business Development, both of Qualicaps Europe, explore how the use of Quali-V® Extra Dry capsules can help improve product stability and, crucially, lead to efficiencies and savings in drug product manufacture. A fundamental requirement in drug common excipients that also fit into this formulation is that the API remains stable category include PEG (low molecular under specific ICH environmental conditions weight), glycerine fatty acid esters or medium and in the finished dosage form until the end chain fatty acid triglycerides, sorbitol, of its shelf life to ensure efficacy and patient maltodextrin, citric acid, microcrystalline safety. The physical and chemical properties cellulose (MCC), polyvinylpyrrolidone of pharmaceutical solids are critically (PVP), croscarmellose sodium, sodium dependent on the presence of water/ chloride, sodium sulphate, ammonium moisture, e.g. during compaction, stability, sulphate, amines and calcium chloride. storage, and processing into formulation Inhalable powders are also extremely and final product packaging. Many APIs, sensitive to moisture, as aerosolisation as well as excipients, are moisture sensitive properties and drug delivery performance and/or hygroscopic in nature and need can be greatly impacted by the amount of to be protected as moisture can have a moisture present in the formulation. Particle Jose Luis Encinas possible negative effect on their potency aggregation due to moisture affects the Engineering & Continuous or strength, result in chemical degradation emitted dose – that is, the powder released Improvement Manager and/or polymorph forms, and could also from the capsule and device – as well as T: +34 91 663 0874 E: [email protected] potentially affect capsule characteristics.
    [Show full text]
  • Vitamin A, E, & D Unit Change
    Vitamin A, E, & D Unit Change Agenda The following provides an overview of the updated units that NQAC Dublin will be using to adhere to FDA guideline changes regarding Nutrition and Supplement Facts labels. This presentation will review: • FDA Guidelines • Methods Affected • Unit Changes by Vitamin • Conversions In August of 2019, the FDA updated its guideline requirements for Nutrition and Supplement Facts labels regarding vitamin A, vitamin D, and vitamin E. The following link can be used to access the FDA guidelines directly: www.fda.gov/regulatory-information Which methods are affected by this change? • LI-00.608 –Multi Fat • LI-03.701 –Fat Soluble Vitamin Determination in Premixes • LI-00.683- Carotene • GOP-756-1001- Total Vitamin A by Calculation (will be obsoleted) FDA Provided Unit Conversion Table: Vitamin A The previous RDI for vitamin A was expressed in International Units (IU), a measurement based on the biological activity or effect, where one IU of vitamin A activity had been defined as equal to 0.30 mcg of all-trans-retinol or 0.60 mcg of all-trans-β-carotene The new unit of measure, RAE, considers the vitamin A activity of β-carotene in supplements to be half the activity of pre-formed retinol, and the vitamin A activity of dietary β-carotene to be one- sixth of the β-carotene in supplements Furthermore, carotenoids, such as β-carotene, added to food is assumed to have the same bioconversion as those naturally occurring in foods (12:1). For the other dietary provitamin A carotenoids, β-cryptoxanthin and α-carotene, the RAE is set at 24 based on a vitamin A activity approximately half of that for β-carotene.
    [Show full text]
  • A Clinical Update on Vitamin D Deficiency and Secondary
    References 1. Mehrotra R, Kermah D, Budoff M, et al. Hypovitaminosis D in chronic 17. Ennis JL, Worcester EM, Coe FL, Sprague SM. Current recommended 32. Thimachai P, Supasyndh O, Chaiprasert A, Satirapoj B. Efficacy of High 38. Kramer H, Berns JS, Choi MJ, et al. 25-Hydroxyvitamin D testing and kidney disease. Clin J Am Soc Nephrol. 2008;3:1144-1151. 25-hydroxyvitamin D targets for chronic kidney disease management vs. Conventional Ergocalciferol Dose for Increasing 25-Hydroxyvitamin supplementation in CKD: an NKF-KDOQI controversies report. Am J may be too low. J Nephrol. 2016;29:63-70. D and Suppressing Parathyroid Hormone Levels in Stage III-IV CKD Kidney Dis. 2014;64:499-509. 2. Hollick MF. Vitamin D: importance in the prevention of cancers, type 1 with Vitamin D Deficiency/Insufficiency: A Randomized Controlled Trial. diabetes, heart disease, and osteoporosis. Am J Clin Nutr 18. OPKO. OPKO diagnostics point-of-care system. Available at: http:// J Med Assoc Thai. 2015;98:643-648. 39. Jetter A, Egli A, Dawson-Hughes B, et al. Pharmacokinetics of oral 2004;79:362-371. www.opko.com/products/point-of-care-diagnostics/. Accessed vitamin D(3) and calcifediol. Bone. 2014;59:14-19. September 2 2015. 33. Kovesdy CP, Lu JL, Malakauskas SM, et al. Paricalcitol versus 3. Giovannucci E, Liu Y, Rimm EB, et al. Prospective study of predictors ergocalciferol for secondary hyperparathyroidism in CKD stages 3 and 40. Petkovich M, Melnick J, White J, et al. Modified-release oral calcifediol of vitamin D status and cancer incidence and mortality in men.
    [Show full text]